Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Thoracic Cancer
|
April 10, 2019
Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report
Ryuya Edahiro, Mikako Ishijima, Hiroyuki Kurebe, et al.
Annals of Translational Medicine
|
January 1, 2019
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression
Takeshi Uenami, Mikako Ishijima, Masaki Kanazu, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|
November 3, 2018
Improvement of exertional dyspnea and breathing pattern of inspiration to expiration after bronchial thermoplasty
Keisuke Miki, Mari Miki, Kenji Yoshimura, et al.
American Journal of Physiology. Cell Physiology
|
November 29, 2013
Oxidative stress-inducible truncated serine/arginine-rich splicing factor 3 regulates interleukin-8 production in human colon cancer cells
Shizuka Kano, Kensei Nishida, Hiroyuki Kurebe, et al.
Journal of Breath Research
|
January 12, 2018
Exercise tolerance and balance of inspiratory-to-expiratory muscle strength in relation to breathing timing in patients with chronic obstructive pulmonary disease
Keisuke Miki, Kazuyuki Tsujino, Ryuya Edahiro, et al.
Plos One
|
August 29, 2018
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study
Yukihiro Yano, Hiroyuki Kurebe, Ryuya Edahiro, et al.
Thoracic Cancer
|
June 23, 2020
Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions
Satoshi Tobita, Yuhei Kinehara, Yoshio Tamura, et al.
Plos One
|
August 1, 2019
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
Ryuya Edahiro, Masaki Kanazu, Hiroyuki Kurebe, et al.
Internal Medicine (Tokyo, Japan)
|
October 19, 2018
Three Cases of Idiopathic Diffuse Pulmonary Ossification
Ryuya Edahiro, Hiroyuki Kurebe, Saeko Nakatsubo, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Thoracic Cancer
|
April 10, 2019
Continued administration of pembrolizumab for adenocarcinoma of the lung after the onset of fulminant type 1 diabetes mellitus as an immune-related adverse effect: A case report
Ryuya Edahiro, Mikako Ishijima, Hiroyuki Kurebe, et al.
Annals of Translational Medicine
|
January 1, 2019
Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression
Takeshi Uenami, Mikako Ishijima, Masaki Kanazu, et al.
Allergy, Asthma, and Clinical Immunology : Official Journal of the Canadian Society of Allergy and Clinical Immunology
|
November 3, 2018
Improvement of exertional dyspnea and breathing pattern of inspiration to expiration after bronchial thermoplasty
Keisuke Miki, Mari Miki, Kenji Yoshimura, et al.
American Journal of Physiology. Cell Physiology
|
November 29, 2013
Oxidative stress-inducible truncated serine/arginine-rich splicing factor 3 regulates interleukin-8 production in human colon cancer cells
Shizuka Kano, Kensei Nishida, Hiroyuki Kurebe, et al.
Journal of Breath Research
|
January 12, 2018
Exercise tolerance and balance of inspiratory-to-expiratory muscle strength in relation to breathing timing in patients with chronic obstructive pulmonary disease
Keisuke Miki, Kazuyuki Tsujino, Ryuya Edahiro, et al.
Plos One
|
August 29, 2018
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study
Yukihiro Yano, Hiroyuki Kurebe, Ryuya Edahiro, et al.
Thoracic Cancer
|
June 23, 2020
Successful continuous nivolumab therapy for metastatic non-small cell lung cancer after local treatment of oligometastatic lesions
Satoshi Tobita, Yuhei Kinehara, Yoshio Tamura, et al.
Plos One
|
August 1, 2019
Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan
Ryuya Edahiro, Masaki Kanazu, Hiroyuki Kurebe, et al.
Internal Medicine (Tokyo, Japan)
|
October 19, 2018
Three Cases of Idiopathic Diffuse Pulmonary Ossification
Ryuya Edahiro, Hiroyuki Kurebe, Saeko Nakatsubo, et al.
Page
of 1